GRAIL, Inc. Common Stock (GRALV) Stock
GRAIL, LLC is a biotechnology firm dedicated to pioneering solutions for the early identification of cancer. The company offers Galleri, a multi-cancer early detection screening test designed for healthy individuals aged 50 and above who show no symptoms.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Peer Comparison
About GRAIL, Inc. Common Stock
GRAIL, LLC is a biotechnology firm dedicated to pioneering solutions for the early identification of cancer. The company offers Galleri, a multi-cancer early detection screening test designed for healthy individuals aged 50 and above who show no symptoms. Additionally, it provides DAC, a diagnostic assistance tool aimed at accelerating the diagnostic process for patients with a clinical suspicion of cancer. Beyond initial detection and diagnosis, GRAIL is also engaged in developing tests for minimal residual disease (MRD) and other post-treatment monitoring applications. Established in 2015, the company originally operated as PSC15, Inc. before rebranding as GRAIL, LLC in January 2016. Headquartered in Menlo Park, California, GRAIL, LLC functions as a subsidiary of Illumina, Inc.
GRAIL, Inc. Common Stock is headquartered in US.
GRAIL, Inc. Common Stock (GRALV) stock trades at $18.63 with a market capitalization of $579.39M. Over the past 52 weeks the stock has ranged between $12.51 and $23.36, and currently trades 20.2% below its 52-week high.
Official website: grail.com